Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certepetide in metastatic pancreatic cancer (China)
NCT05052567Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of certepetide in pancreatic ductal adenocarcinoma (PDAC), sponsored by Qilu Pharmaceutical. Primary endpoints: Adverse Events and Serious Adverse Events at 12 months, Objective Response Rate at 12 months and 5 more. Started Oct 2021; status: completed.
02
Drugs
certepetide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05052567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052567.